ReviewAnnals of medicine2024
Advances in targeted therapy of cholangiocarcinoma.
Review in Annals of medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 35 citations in OpenAlex.
- Erdafitinib in Patients with FGFR-Altered Advanced or Metastatic Cholangiocarcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Development and Validation of a Crotonylation-Related Prognostic Risk Model for Cholangiocarcinoma Based on Integrative Transcriptome Analysis.Digestive diseases and sciences · 2026Article
- Development and frontier trends of research on the gut microbiota and cholangiocarcinoma.Surgery open science · 2026Article
- Review
- MiR-7-5p suppresses TGF-β-induced glycolysis and proliferation in intrahepatic cholangiocarcinoma by targeting MyD88.Human cell · 2026Article
- Carcinogenic role of ESCO2 in cholangiocarcinoma: integration of bioinformatics analysis and experimental validation.Translational cancer research · 2026Article
- CBC3T-3: a novel patient-derived cisplatin-resistant distal cholangiocarcinoma cell line harboring multiple TP53 missense mutations.Human cell · 2026Article
- Microbial dysbiosis in cholangiocarcinoma.Frontiers in microbiology · 2026Review
- LncRNA PVT1 promotes proliferation, migration and invasion of cholangiocarcinoma by regulating the expression of SOCS2.Scientific reports · 2025Article
- Second-Line Treatment in cholangiocarcinoma - Current State of the Art and Future Perspectives.Current treatment options in oncology · 2025Review
- Computational Investigation Identifies mTOR as a Primary Binding Target of Medicarpin in Cholangiocarcinoma: Insights from Network Pharmacology and Molecular Docking.Life (Basel, Switzerland) · 2025Article
- Construction and validation of gene signature for prognosis and drug sensitivity in cholangiocarcinoma based on cellular senescence related genes.Scientific reports · 2025Article
- Advances in Multi-Omics Research on Biomarkers of Intrahepatic Cholangiocarcinoma.Current issues in molecular biology · 2025Review
- Development and validation of a nomogram comprising GLUT1 and clinical characteristics for predicting overall survival in intrahepatic cholangiocarcinoma.Translational cancer research · 2025Article
- Evaluating Novel Braided Metal Stent for Bilateral Simultaneous Side-by-Side Stenting in Malignant Hilar Biliary Obstruction: A Multicenter, Single-Arm Prospective Study.Journal of clinical medicine · 2025Article
- Progress in precision therapies for advanced cholangiocarcinoma: inhibitors of FGFR1-3.Journal of gastrointestinal oncology · 2025Article
- Role of miRNA‑145‑5p in cancer (Review).Oncology reports · 2025Review
- Significant Response to Palbociclib Plus Lenvatinib as Second-line Treatment for CDKN2A/2B Deletion Intrahepatic Cholangiocarcinoma: A Case Report.Journal of clinical and translational hepatology · 2025Article
- ADAMDEC1 promotes the malignant progression of cholangiocarcinoma by regulating NF-κB signaling pathway.Scientific reports · 2025Article
- Metabolic crossroads: unravelling immune cell dynamics in gastrointestinal cancer drug resistance.Cancer drug resistance (Alhambra, Calif.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cholangiocarcinoma (CCA) is a malignant tumor originating in the bile duct and its branching epithelium. Due to its high heterogeneity, there are no specific clinical indications at the early stage, the diagnosis is often in advanced CCA. With surgical resection, the 5-year postoperative survival rate (long-term survival rate) is very poor. The regimen of gemcitabine combined with platinum has been used as the first-line chemotherapy for advanced patients. In recent years, targeted therapy for a variety of malignant tumors has made great progress, showing good efficacy and safety in advanced CCA. However, the current targeted therapy of CCA still has many challenges, such as adverse reactions, drug resistance, and individual differences. Therefore, the researches need to further explore the targeted therapy mechanism of CCA malignancies in depth, develop more effective and safe drugs, and accurately formulate plans based on patient characteristics to further improve patient prognosis in the future. This article reviews the recent progress of targeted therapy for CCA, aiming to provide a strategy for the research and clinical work of targeted therapy for CCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.